Trial · NCT07891156
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.
NCT07891156, Phase 2, Phase 3, Recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. Trials, record NCT07891156. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891156
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.
- NCT number
- NCT07891156
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 40 participants, estimated
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Conditions
- Type 1 Diabetes, Overweight , Obesity
- Interventions
- Semaglutide, Placebo
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in lean mass | Baseline to 24 weeks of study drug use | Change in total lean mass, measured in kilograms (kg). |
| Secondary | Fat mass (kilograms) | Baseline to 24 weeks | Change in total fat mass measured in kilograms (kg) using dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Proportion of lean mass to fat mass (percentage) | Baseline to 24 weeks | Change in the proportion of lean mass relative to fat mass as a percentage (%), measured using dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Bone density (grams per cubic centimetre) | Baseline to 24 weeks | Change in bone density measured in grams per cubic centimetre (g/cm³) using dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Appendicular lean mass and visceral fat mass (kilograms) | Baseline to 24 weeks | Change in appendicular lean mass and visceral fat mass measured in kilograms (kg) using dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Weight (kilograms) | Baseline to midpoint (weeks 15-16) and 24 weeks | Change in body weight, measured in kilograms (kg), on an electronic scale. |
| Secondary | Hip circumference (centimetres) | Baseline to midpoint (weeks 15-16) and 24 weeks | Change in hip circumference, measured in centimetres (cm). Use a measuring tape to measure the largest circumference around the buttock area. |
| Secondary | Waist circumference (centimetres) | Baseline to midpoint (weeks 15-16) and 24 weeks | Change in waist circumference, measured in centimetres (cm) using anthropometric measurements. Use a measuring tape to measure at the level of the ischial crests as a landmark. |
| Secondary | Blood pressure (millimeters of mercury) | Baseline to 24 weeks | Change in blood pressure, measured in millimetres of mercury (mmHg), after a 5-minute reset, measured 3 times. We will average the 3 values. |
| Secondary | Mean peak torque | Baseline to 24 weeks | Change in mean peak torque during isokinetic and isometric knee extension/flexion, measured via Biodex. Results will be recorded as weight-based torque (Nm/kg). |
1 to 10 of 34Source ClinicalTrials.gov
See all 34 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891156
GET https://conductscience.org/api/trials/v1/NCT07891156/registered?page=2